The First New Hair Loss Drug in 30 Years: Clascoterone Shows Up to 539% Improvement in Phase 3 Trials

For three decades, men facing hair loss have had exactly two FDA-approved pharmaceutical options: minoxidil (the topical treatment, approved 1988) and finasteride (the oral pill, approved 1997). Both work. Both have limitations. And for 30 years, nothing new has come along to join them.

That's about to change. In late 2025, Cosmo Pharmaceuticals published Phase 3 clinical trial results for clascoterone 5% topical solution — and the data is the most significant hair loss news in a generation.

What Is Clascoterone?

Clascoterone is a topical androgen receptor inhibitor. If that sounds technical, here's the simple version: it blocks DHT (dihydrotestosterone) at the hair follicle — the same hormone that causes male pattern hair loss — without affecting DHT levels anywhere else in your body.

This is the critical distinction. Finasteride works systemically — it reduces DHT throughout your entire body by blocking the enzyme that converts testosterone to DHT. That's effective for hair, but it's also why finasteride carries side effects like reduced libido and sexual dysfunction in a small percentage of users. Those side effects, even though they're uncommon, have made a lot of men reluctant to try the only pill that actually works.

Clascoterone takes a targeted approach. Applied directly to the scalp, it binds to androgen receptors on hair follicles and blocks DHT from shrinking them — without measurable absorption into the bloodstream. The drug stays where you put it.

The Phase 3 Results

Cosmo ran two large, identically designed trials — SCALP 1 and SCALP 2 — enrolling a combined total of 1,465 men across the United States and Europe. Both were randomized, double-blind, and vehicle-controlled (meaning half the participants used the active treatment and half used a lookalike placebo). Each trial had a 6-month double-blind phase followed by a 6-month extension.

The numbers:

SCALP 1: Clascoterone produced a 539% relative improvement in target area hair count (TAHC) compared to the vehicle group.

SCALP 2: A 168% relative improvement in TAHC.

The variation between the two trials isn't unusual in hair loss research — results depend on factors like baseline severity, regional demographics, and assessment technique. But the direction is consistent across both: statistically significant hair regrowth.

Patient-reported outcomes tracked with the objective data. One trial met its patient-reported endpoint, the other showed a favorable trend, and combined analysis across both was statistically significant. In practical terms: men didn't just grow more hair on paper — they noticed and reported the difference themselves.

The safety profile was reassuring. Treatment-emergent adverse events were similar between the clascoterone and vehicle groups, most were mild and unrelated to the drug, and — crucially — no sexual side effects were reported.

That last point is the headline for a lot of men. A topical treatment that works at the follicle, doesn't enter systemic circulation, and carries no reported sexual side effects addresses the primary concern that's kept many men away from finasteride for decades.

How It Compares to Existing Treatments

Here's how clascoterone slots into the current landscape:

Minoxidil (Rogaine)

• Mechanism: Vasodilator — increases blood flow to the scalp
• Form: Topical (liquid or foam), applied twice daily
• Strengths: Available over the counter, well-tolerated
• Limitations: Doesn't address the hormonal cause of hair loss; mainly slows loss rather than regrowing hair; must be used indefinitely

Finasteride (Propecia)

• Mechanism: Systemic DHT blocker — reduces DHT production throughout the body
• Form: Oral pill, taken daily
• Strengths: Effective at both halting loss and regrowing hair
• Limitations: Systemic side effects possible (sexual dysfunction in ~2-4% of users); requires ongoing use; some men are psychologically deterred by the side effect profile

Clascoterone (pending)

• Mechanism: Topical androgen receptor inhibitor — blocks DHT at the follicle only
• Form: Topical solution, applied to the scalp
• Strengths: Targets the root cause (DHT) without systemic exposure; no reported sexual side effects; strong Phase 3 data
• Limitations: Not yet approved; long-term data still accumulating; requires ongoing use

JAK Inhibitors (Olumiant, Litfulo, Leqselvi)

• Mechanism: Immune modulators
• Form: Oral pills
• What they treat: Alopecia areata (autoimmune hair loss) — not androgenetic alopecia (pattern baldness)
• Important distinction: These won't help with standard male pattern hair loss

What About PP405?

Another compound generating excitement is PP405, a topical treatment from Pelage Pharmaceuticals that targets hair follicle stem cells. Phase 2a results showed that 31% of men with more advanced hair loss achieved over 20% increases in hair density — with no systemic absorption.

PP405 works through a different mechanism than clascoterone: instead of blocking DHT, it "wakes up" dormant follicle stem cells. TIME magazine named it one of the best inventions of 2025, and Phase 3 trials are expected to begin in 2026.

However, experts urge measured expectations. "PP405 and other early-stage treatments are very early, and the level of online excitement is far ahead of the actual data," noted one industry observer. Long-term durability and real-world effectiveness remain unknown.

Timeline: When Can You Actually Get Clascoterone for Hair Loss?

Cosmo Pharmaceuticals is completing the required 12-month safety follow-up, with data expected in spring 2026. After that, parallel FDA and EMA (European) submissions are planned.

If the regulatory path goes smoothly — and Phase 3 data this strong typically bodes well — clascoterone 5% topical solution could reach the market by late 2026 or 2027. It would become the first topical androgen receptor inhibitor specifically indicated for androgenetic alopecia.

Worth noting: clascoterone 1% cream is already FDA-approved and on the market for acne (sold as Winlevi), with over 1.5 million U.S. prescriptions since its 2020 launch. So the active ingredient has an established safety track record — just at a lower concentration and for a different indication.

What This Means for You

If you're currently managing hair loss, the near-term advice hasn't changed: minoxidil and finasteride remain the proven, available options. Talk to a dermatologist about which (or which combination) makes sense for your situation.

But if you've been on the fence — particularly if finasteride's side effect profile has been the sticking point — there's now a genuine reason for optimism on the horizon. A locally-acting treatment that blocks DHT without systemic effects is exactly what many men have been waiting for.

The 30-year drought appears to be ending. And clascoterone is just the beginning — the pipeline behind it, from PP405 to stem cell-based approaches, is deeper than it's ever been.

Your hair loss isn't a solved problem yet. But it's a problem that finally has new answers coming.

This article is for informational purposes only and is not medical advice. Consult a dermatologist for personalized hair loss treatment guidance.